Who is sponsoring NCT00163761?

NCT00163761 is sponsored by Bayside Health.

What drugs are being tested in NCT00163761?

Interventions in NCT00163761: gemcitabine, vinorelbine, ifosfamide, filgastrim, gemcitabine, vinorelbine, filgastrim.

What condition does NCT00163761 study?

NCT00163761 studies Non-Hodgkin's Lymphoma, Hodgkin's Disease.

Is NCT00163761 still recruiting?

NCT00163761 is currently completed. Last updated 6 January 2016.

Last reviewed 2016-01-06 · How we verify

NCT00163761

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Multicentre Phase II Study of Risk-adjusted Outpatient-based Salvage Therapy for Patients With Relapsed and Refractory Lymphoma

Completed Phase 2 Last updated 6 January 2016

What this trial tests

Phase 2 trial testing gemcitabine, vinorelbine, ifosfamide, filgastrim in Non-Hodgkin's Lymphoma in 90 participants. Completed in 1 February 2008.

Timeline

1 December 2002

Primary endpoint
1 February 2008

1 February 2008

Quick facts

Lead sponsor	Bayside Health
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	crossover
Masking	none
Primary purpose	treatment
Enrollment	90
Start date	1 December 2002
Primary completion	1 February 2008
Estimated completion	1 February 2008
Sites	10 locations across Australia

Drugs / interventions tested

gemcitabine, vinorelbine, ifosfamide, filgastrim — full drug profile →
gemcitabine, vinorelbine, filgastrim — full drug profile →

Conditions studied

Non-Hodgkin's Lymphoma — all drugs for Non-Hodgkin's Lymphoma →
Hodgkin's Disease — all drugs for Hodgkin's Disease →

Sponsor

Bayside Health — full company profile →

Who can join

18 and older, any sex, with Non-Hodgkin's Lymphoma or Hodgkin's Disease. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

To evaluate the efficacy (overall response rate) of a risk-adjusted outpatient-based approach to lymphoma salvage therapy with VGF (vinorelbine, gemcitabine and pegfilgrastim) and/or F-GIV (gemcitabine, Ifosfamide, vinorelbine and pegfilgrastim).
Time frame: After two cycles and after four cycles

Sponsor's own description

This is a Phase II trial evaluating the efficacy (overall response rate) of a risk-adjusted outpatient based approach to lymphoma salvage therapy with vinorelbine, gemcitabine and pegfilgrastim and/or gemcitabine, ifosfamide, vinorelbine and pegfilgrastim.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Non-Hodgkin's Lymphoma

Currently open trials in the same condition.

NCT07202052 — Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT) · Phase 2, PHASE3 · recruiting
NCT06208735 — CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies · Phase 1 · recruiting
NCT06343311 — T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) · Phase 1, PHASE2 · recruiting
NCT05884333 — Cord Blood Transplant in Adults With Blood Cancers · Phase 2 · recruiting
NCT04532203 — A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological Maligna · EARLY_PHASE1 · recruiting

Other Bayside Health trials

Trials by the same sponsor.

NCT05852301 — Optimising Cohorts for HIV Cure Interventions · unknown
NCT05470816 — Tranexamic Acid to Reduce Delirium After Gastrointestinal Surgery: the TRIGS-D Trial · Phase 3 · active not recruiting
NCT04192435 — Tranexamic Acid to Reduce Infection After Gastrointestinal Surgery · Phase 4 · completed
NCT04978285 — Association of Postoperative Anaemia With Patient-centred Outcomes · completed
NCT03869736 — Nitrous Oxide for the Treatment of Major Depressive Disorder · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00163761 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bayside Health
Last refreshed: 6 January 2016

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00163761.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing